Study of Olverembatinib (HQP1351) in Patients With CP-CML

A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia

NCT06401603 ·Status: RECRUITING ·Phase: PHASE1

ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)

NCT06378138 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia

NCT04258943 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

NCT04260022 ·Status: RECRUITING ·Phase: PHASE1

Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase

NCT00383474 ·Status: COMPLETED ·Phase: PHASE1

CML Treated With Bosutinib After Relapse

NCT02445742 ·Status: COMPLETED ·Phase: PHASE2

A Study of Olverembatinib in the Treatment of Ph+ ALL

NCT05466175 ·Status: UNKNOWN ·Phase: PHASE2

Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008

NCT01903733 ·Status: COMPLETED ·Phase: NA

A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALL

NCT05931757 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands

NCT02546375 ·Status: COMPLETED

Decitabine and HQP1351-based Chemotherapy Regimen for the Treatment Advanced CML

NCT05376852 ·Status: UNKNOWN ·Phase: PHASE2

Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

NCT01274351 ·Status: COMPLETED ·Phase: PHASE2

Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia

NCT00816283 ·Status: COMPLETED ·Phase: PHASE1

Assess Long-term Feasibility of Reduced Dose Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients

NCT04150471 ·Status: UNKNOWN

Phase II Study Testing the Tolerability and the Efficacy of Bosutinib in Chronic Phase CML Patients

NCT03205267 ·Status: UNKNOWN ·Phase: PHASE2

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

NCT02130557 ·Status: COMPLETED ·Phase: PHASE3

Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia

NCT01670084 ·Status: WITHDRAWN ·Phase: PHASE2

Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid Leukemia

NCT00510939 ·Status: UNKNOWN ·Phase: PHASE2

Bortezomib in Treating Patients With Chronic Myelogenous Leukemia

NCT00023881 ·Status: TERMINATED ·Phase: PHASE2

Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL

NCT06481241 ·Status: RECRUITING ·Phase: NA

A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON)

NCT01300247 ·Status: COMPLETED ·Phase: PHASE1

Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib

NCT00644878 ·Status: TERMINATED ·Phase: PHASE2

A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.

NCT06566742 ·Status: RECRUITING ·Phase: PHASE2

CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

NCT03896269 ·Status: RECRUITING ·Phase: PHASE1

Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.

NCT02315768 ·Status: COMPLETED ·Phase: PHASE1/PHASE2